Pharmaceutical

Risk adjusted net present value: What is the current valuation of Merck’s MK-0616?

MK-0616 is a peptide commercialized by Merck, with a leading Phase III program in Heterozygous familial hypercholesterolemia (heFH).

Sep 19, 2023 - 20:00
Risk adjusted net present value: What is the current valuation of Merck’s MK-0616?
MK-0616 is a peptide commercialized by Merck, with a leading Phase III program in Heterozygous familial hypercholesterolemia (heFH).
Read the original article

Tags:

Previous Article

Risk adjusted net present value: What is the current valuation of AstraZeneca’s ...

Next Article

Kroger Health Joins Hands With Performance Kitchen to Provide Medically Tailored...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Meitheal gains rights to CONTEPO from Nabriva in North America

Meitheal gains rights to CONTEPO from Nabriva in North ...

Jul 20, 2024

STAT+: Morphic study shows promise — and blockbuster potential — for a pill to treat ulcerative colitis

STAT+: Morphic study shows promise — and blockbuster po...

Apr 25, 2023

How the GLP-1 receptor agonist market could hit $168bn by 2033

How the GLP-1 receptor agonist market could hit $168bn ...

Aug 11, 2024